Volume | 0.00 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Biostage Inc (QB) | BSTG | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
4.45 | 4.45 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0.00 | - | 3.65 - 4.57 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 4.45 | USD |
Biostage Inc (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
61.77M | 13.88M | 7.41M | 103k | -9.02M | -0.65 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Biostage (QB) News
Date | Time | Source | News Article |
---|---|---|---|
4/29/2024 | 08:00 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
4/17/2024 | 16:08 | Edgar (US Regulatory) | Form 8-K - Current report |
3/28/2024 | 16:08 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K.. |
11/13/2023 | 10:59 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
9/18/2023 | 09:04 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
8/28/2023 | 09:13 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
8/14/2023 | 14:13 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
7/28/2023 | 15:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
7/28/2023 | 15:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
7/28/2023 | 15:00 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BSTG Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 4.57 | 4.57 | 3.65 | 4.00 | 2,187 | -0.12 | -2.63% |
3 Years | 1.21 | 9.00 | 1.12 | 4.41 | 3,087 | 3.24 | 267.77% |
5 Years | 2.55 | 9.00 | 0.55 | 3.24 | 3,004 | 1.90 | 74.51% |
Biostage (QB) Description
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology combines the synthetic scaffold with tissue engineering and cell biology to create method of addressing organ damage. Its Cellframe technology stimulates the body's signaling pathways and natural healing process to regenerate and restore organ function. The company is developing organ implants as a platform of being used in the esophagus, trachea, and bronchi. Its implants are being advanced and tested in preclinical collaborative studies with Mayo Clinic and Connecticut Children's Medical Center. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2012 and is headquartered in Holliston, Massachusetts. |